Cogent Biosciences

ACTR707 is a monoclonal antibody (mAb) in development by Cogent Biosciences for lymphoma. The program carries the internal code ATTCK-20-03 and was evaluated in a Phase 1 clinical trial (NCT03189836). The mechanism of action and specific target have not been disclosed. Cogent Biosciences is developing this asset independently without a disclosed partner or licensing arrangement. The program was terminated as of October 11, 2021, marking the end of active development. No regulatory filings, approvals, or peak sales projections have been disclosed. The termination occurred during Phase 1 evaluation, prior to advancement to later-stage clinical development.

Lymphoma represents a significant oncology indication with substantial unmet medical needs, particularly for patients with relapsed, refractory, or treatment-resistant disease. The competitive landscape includes multiple approved therapies spanning small-molecule kinase inhibitors (ibrutinib, crizotinib, temsirolimus), antibody-based approaches (brentuximab vedotin, denileukin difitox), and several candidates in Phase 3 development. Monoclonal antibodies have demonstrated clinical utility in lymphoma through multiple mechanisms, including direct cytotoxicity, antibody-dependent cellular cytotoxicity, and checkpoint modulation. The termination of ACTR707 suggests that Cogent Biosciences made a strategic decision to discontinue this particular mAb candidate, potentially due to preclinical findings, early clinical safety or efficacy signals, or portfolio prioritization. The program's Phase 1 stage at termination indicates that clinical proof-of-concept had not been established. The lymphoma market remains competitive with both approved and investigational agents addressing various histologic subtypes and disease states, creating ongoing opportunities for differentiated therapeutic approaches.

Drug Class: Monoclonal antibody (mAb)

Modality: Biologic—humanized or fully human antibody

Mechanism of Action: Not yet disclosed

Target: Not yet disclosed

Route of Administration: Not yet disclosed

Indication: Lymphoma

Related Therapies: Other mAbs in lymphoma include brentuximab vedotin (anti-CD30, Takeda) and denileukin difitox (anti-CD25, Ligand Pharmaceuticals). Small-molecule alternatives include ibrutinib (BTK inhibitor, AbbVie), temsirolimus (mTOR inhibitor, Pfizer), and crizotinib (ALK/ROS1 inhibitor).

Patent Status: Not yet disclosed

First Approval: Not applicable—program terminated in Phase 1

FDA Status: Not yet disclosed. Program terminated prior to IND advancement or regulatory submissions.

EMA Status: Not yet disclosed.

PMDA (Japan) Status: Not yet disclosed.

NMPA (China) Status: Not yet disclosed.

Regulatory History: ACTR707 was evaluated under clinical trial NCT03189836. No regulatory filings, breakthrough designations, orphan drug designations, or approvals have been disclosed. The program's termination in October 2021 during Phase 1 indicates no regulatory pathway advancement occurred.

Strategic Implications: Cogent Biosciences' termination of ACTR707 reflects portfolio prioritization and resource allocation decisions. The Phase 1 discontinuation suggests early-stage clinical or preclinical findings did not support continued development relative to the company's strategic priorities or competitive positioning.

Competitive Implications: The lymphoma mAb space remains active, with brentuximab vedotin established as a standard-of-care option and multiple Phase 3 candidates advancing. ACTR707's exit does not materially alter the competitive landscape but underscores the high bar for mAb differentiation in this indication.

Future Catalysts: None anticipated for ACTR707, as the program is terminated. Cogent Biosciences' pipeline strategy and any successor lymphoma programs remain to be disclosed.

Expected Milestones: No further milestones are expected for ACTR707. Investors should monitor Cogent Biosciences' disclosure of alternative lymphoma or oncology programs.